Skip to main content

HLA DQB1 CWD Resolution

CPT

81382

Synonyms
  • CWD Resolution Typing
  • Share
  • Print
  • Updated on 04/14/2025

Test Details

Methodology

HLA results are obtained using Next Generation Sequencing (NGS). 

Sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain the required resolution.

HLA results are obtained using Next Generation Sequencing (NGS). 

Result Turnaround Time

3 - 7 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

DQB1 antigens may be correlated with certain disease states or other clinical conditions. Also used for screening of transplant candidates and potential donors, transfusion of specifically compatible blood products, among others. This test is for single locus typing at CWD or higher resolution.

CWD resolution typing for HLA will meet the following criteria:

1. The typing must contain only one unambiguously assigned genotype, or

2. The typing may contain multiple alternative genotypes if one includes two Common and Well Documented (CWD) alleles and the others do not include any CWD allele. Alleles that encode identical protein sequences in the antigen recognition site (ARS) will not be resolved even if they are CWD.

3. Rare or unusual allele combinations may not be ruled out.

4. Allele codes will be reported to include those alleles that are not ruled out.

Common and well documented alleles are defined by Cano et al1 and Mack et al.2

Special Instructions

Indicate in clinical information which antigen(s) is of interest. If you have questions, please call 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.

Limitations

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen Requirements

Specimen

Whole blood

Volume

7 mL

Minimum Volume

3 mL

Container

Lavender-top (EDTA) tube

Storage Instructions

Maintain specimen at room temperature; protect from extreme heat or cold. Do not freeze.

Causes for Rejection

Hemolyzed specimen; clotted specimen; wrong specimen container

Footnotes

1. Cano P, Klitz W, Mack SJ, et al. Common and well-documented HLA alleles: Report of the ad-hoc committee of the American Society for Histocompatibility and Immunogenetics. Hum Immunol. 2007 May; 68(5):392-417. 17462507
2. Mack SJ, Cano P, Hollenbach JA, et al. Common and Well-Documented HLA Alleles: 2012 Update to the CWD Catalogue. Tissue Antigens. 2013 Apr; 81(4):194-203. 23510415

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
167095 HLA DQB1 (CWD) 167233 HLA DQB Sequencing 57299-0
167095 HLA DQB1 (CWD) 167234 HLA DQB Sequencing 57299-0
167095 HLA DQB1 (CWD) 167384 HLA Methodology 49549-9
Order Code167095
Order Code NameHLA DQB1 (CWD)
Order Loinc
Result Code167233
Result Code NameHLA DQB Sequencing
UofM
Result LOINC57299-0
Order Code167095
Order Code NameHLA DQB1 (CWD)
Order Loinc
Result Code167234
Result Code NameHLA DQB Sequencing
UofM
Result LOINC57299-0
Order Code167095
Order Code NameHLA DQB1 (CWD)
Order Loinc
Result Code167384
Result Code NameHLA Methodology
UofM
Result LOINC49549-9